Related Experiment Videos
Gene therapy for rheumatoid arthritis
Natacha Bessis1, Christelle Doucet, Virginie Cottard
1UPRES EA-3408 (Université Paris 13) and Service de Rhumatologie (CHU Avicenne, AP-HP), Bobigny, France. bessis@smbh.univ-paris13.fr
Abstract:
Rheumatoid arthritis (RA) is a severe autoimmune systemic disease. Chronic synovial inflammation results in destruction of the joints. No conventional treatment is efficient in RA. Gene therapy of RA targets mainly the players of inflammation or articular destruction: TNF-alpha or IL-1 blocking agents (such as anti-TNF-alpha monoclonal antibodies, soluble TNF-alpha receptor, type II soluble receptor of IL-1, IL-1 receptor antagonist), antiinflammatory cytokines (such as IL-4, IL-10, IL-1), and growth factors. In this polyarticular disease, the vector expressing the therapeutic protein can be administered as a local (intra-articular injection) or a systemic treatment (extra-articular injection). All the main vectors have been used in experimental models, including the more recent lentivirus and adeno-associated virus. Ex vivo gene transfer was performed with synovial cells, fibroblasts, T cells, dendritic cells, and different cells from xenogeneic origin. In vivo gene therapy is simpler, although a less controlled method. Clinical trials in human RA have started with ex vivo retrovirus-expressing IL-1 receptor antagonists and have demonstrated the feasibility of the strategy of gene therapy. The best target remains to be determined and extensive research has to be conducted in preclinical studies.
Insights
Gene therapy offers a promising approach for rheumatoid arthritis (RA) by targeting inflammation and joint destruction. Clinical trials show feasibility, but further research is needed to optimize targets for effective RA treatment.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a severe autoimmune systemic disease causing chronic synovial inflammation and joint destruction.
- Conventional treatments for RA often lack sufficient efficacy.
- Gene therapy presents a novel strategy to combat RA by targeting key inflammatory and destructive pathways.
Purpose of the Study:
- To review the current landscape of gene therapy approaches for rheumatoid arthritis.
- To explore various therapeutic targets, vectors, and administration methods for RA gene therapy.
- To assess the progress and future directions of gene therapy in RA treatment.
Main Methods:
- Review of experimental models and clinical trials in rheumatoid arthritis gene therapy.
- Analysis of different gene therapy strategies targeting inflammation (e.g., TNF-alpha, IL-1) and joint destruction.
- Evaluation of various gene delivery vectors (lentivirus, adeno-associated virus, retrovirus) and administration routes (ex vivo, in vivo).
Main Results:
- Gene therapy targets key players in RA inflammation and joint destruction, including cytokine blockers and anti-inflammatory cytokines.
- Both local (intra-articular) and systemic (extra-articular) administration routes are feasible.
- Various vectors like lentivirus and adeno-associated virus have been utilized in experimental models.
- Ex vivo gene transfer has been performed using diverse cell types.
- Early clinical trials using ex vivo retrovirus-expressing IL-1 receptor antagonists demonstrate the feasibility of RA gene therapy.
Conclusions:
- Gene therapy holds significant potential for treating rheumatoid arthritis.
- Further preclinical research is essential to identify the optimal therapeutic targets and refine gene delivery strategies.
- Clinical trials have confirmed the feasibility of gene therapy for RA, paving the way for future advancements.